Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase II study of recMAGE-A3 + AS01B in metastatic cutaneous melanoma
2007-005203-18Phase 2Terminated
- Sponsor
- GSK
- Start
- Apr 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recMAGE-A3 + AS01B in cutaneous melanoma (CM), sponsored by GSK. Primary endpoint: Safety of ASCI injections. Started Apr 2008; status: terminated.
02
Drugs
recMAGE-A3 + AS01B
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2007-005203-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005203-18.